Abstract
In this issue of Blood, Li et al report mutations in the 3′ untranslated region (3′UTR) of TP53 that modify the expression of p53 and thus its effect on response to therapy in diffuse large B-cell lymphoma (DLBCL) patients.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Prednisone / therapeutic use
-
Rituximab
-
Tumor Suppressor Protein p53 / genetics*
-
Vincristine / therapeutic use
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone